Results 241 to 250 of about 18,871 (325)

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

RAVORA: Phases XVIII–XIX–XX — Consolidated Framework, Verification Protocols, and Stateless Multi-system Analysis

Ravdive, Viktors
openalex   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Colony: a framework for reproducible and easy-to-use data analysis pipelines for biomedical research with singularity containers. [PDF]

Bioinform Adv
Eschner S, Alabdullah M, Dugas M.
europepmc   +1 more source

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

LLM evaluation for thyroid nodule assessment: comparing ACR-TIRADS, C-TIRADS, and clinician-AI trust gap. [PDF]

Front Endocrinol (Lausanne)
Dai X, Xi Y, Hu Y, Ding Q, Zhang Y, Liu H, Chen P, Wang X, Wang W, Zhang C.   +9 more
europepmc   +1 more source

Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth

Addiction, EarlyView.
Abstract Background and Aims In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm‐reduction treatment improved alcohol outcomes and physical health‐related quality of life (PH‐QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.
Silvi C. Goldstein, Nicole H. Weiss, Manshu Yang, Sarah W. Feldstein Ewing, Susan E. Collins   +4 more
wiley   +1 more source

Collective cooperative intelligence. [PDF]

Proc Natl Acad Sci U S A
Barfuss W, Flack J, Gokhale CS, Hammond L, Hilbe C, Hughes E, Leibo JZ, Lenaerts T, Leonard N, Levin S, Madhushani Sehwag U, McAvoy A, Meylahn JM, Santos FP.   +13 more
europepmc   +1 more source

An Efficient Greedy Packet Stateless Routing (E-Gpsr) based Route Extension and Load Balancing in Wireless Sensor Networks

, 2016
V. Shanthi, Somasundareswari
openalex   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source